Develops gene therapies for genetic disorders of the central nervous system, focusing on neurological conditions.
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company specializing in the treatment of both hereditary and acquired diseases. At the forefront of its innovative pipeline are several promising gene therapy candidates. LX2006, based on AAVrh10 technology, targets Friedreich's ataxia (FA) cardiomyopathy, while LX2020 focuses on plakophilin-2 arrhythmogenic cardiomyopathy. Additionally, LX2021 addresses DSP cardiomyopathy, and LX2022 targets hypertrophic cardiomyopathy (HCM) caused by the TNNI3 gene.
Based in New York, New York, Lexeo Therapeutics, Inc. was founded in 2017 with a mission to advance genetic therapies that tackle significant medical challenges. The company's robust portfolio also includes LX1001 for APOE4 homozygous, LX1020, and LX1021 for the same condition, as well as LX1004 aimed at treating CLN2 Batten disease. Lexeo Therapeutics is dedicated to pushing the boundaries of genetic medicine, leveraging cutting-edge technologies to provide transformative treatments for patients with complex genetic disorders.
Driven by a commitment to innovation and patient care, Lexeo Therapeutics, Inc. continues to expand its scientific expertise and therapeutic capabilities. With a strategic focus on developing targeted gene therapies, the company aims to address critical unmet needs in genetic diseases, offering new hope and improved quality of life for affected individuals worldwide.